Technology
Health
Biotechnology

Allogene Therapeutics

$26.27
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-0.15%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell ALLO and other stocks, options, ETFs, and crypto commission-free!

About ALLO

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Read More Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam on November 2017 and is headquartered in South San Francisco, CA.

Employees
122
Headquarters
South San Francisco, California
Founded
2017
Market Cap
3.20B
Price-Earnings Ratio
Dividend Yield
Average Volume
413.98K
High Today
$26.82
Low Today
$26.06
Open Price
$26.50
Volume
476.07K
52 Week High
$35.55
52 Week Low
$21.67

Collections

Technology
Health
Biotechnology
Cancer Prevention
Therapy
Medical
2018 IPO
US

ALLO Earnings

-$10.71
-$7.23
-$3.74
-$0.26
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.46 per share
Actual
-$0.41 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.